 Monoclonal antibodies, MAPs, have shown promise in treating viral infections, including respiratory syncytial virus pneumonia and Ebola virus disease. As the COVID-19 pandemic continues to spread, researchers have turned their attention to developing anti-SARS-CoV-2 MAPs, which are being tested in various stages of clinical trials. These include VIR-7831, Ly, CoV-555, Ly, CoV-016, BGB, DXP593, IGN, CoV-2, and CT, P59. Each MAP works differently, but they all target different parts of the SARS-CoV-2 virus and can neutralize it. The current phase of clinical trials for each MAP is described, along with potential future developments. This article was offered by Marco Tucuri, Sara Ferraro, Irma Convertino, and others.